These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 7493195)

  • 1. Specific considerations for cost-effectiveness studies in AIDS.
    Bozzette SA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S23-7. PubMed ID: 7493195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and assessment of cost-effectiveness studies in AIDS populations.
    Simpson KN
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S28-32. PubMed ID: 7493196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Working toward a common currency: is standardization of cost-effectiveness analysis possible?
    Luce BR
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S19-22. PubMed ID: 7493194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the essentials of economic evaluation.
    Schmid GP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S6-13. PubMed ID: 7493197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness: from whose perspective?
    Hillman AL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S14-8. PubMed ID: 7493193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why isn't increased survival enough?
    Wilson A
    Integration; 1994 Dec; (42):12-5. PubMed ID: 12319124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the cost-effectiveness of pharmacologic therapy: where we've been and where we're going.
    Epstein AM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S1-5. PubMed ID: 7493192
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
    Aggarwal R; Ghoshal UC; Naik SR
    Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV epidemic in Punjab, India: time trends over a decade.
    Sehgal S
    Bull World Health Organ; 1998; 76(5):509-13. PubMed ID: 9868842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of influenza symptoms in healthy children: cost-effectiveness of rapid testing and antiviral therapy.
    Rothberg MB; Fisher D; Kelly B; Rose DN
    Arch Pediatr Adolesc Med; 2005 Nov; 159(11):1055-62. PubMed ID: 16275797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.
    Langtry HD; Palmer KJ; Benfield P
    Pharmacoeconomics; 1993 Apr; 3(4):309-37. PubMed ID: 10146993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic impact of delaying or preventing AIDS in persons with HIV.
    Pinkerton SD; Holtgrave DR
    Am J Manag Care; 1999 Mar; 5(3):289-98. PubMed ID: 10351025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic consequences of HIV/AIDS in India.
    Pandav CS; Anand K; Shamanna BR; Chowdhury S; Nath LM
    Natl Med J India; 1997; 10(1):27-30. PubMed ID: 9069706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
    Bennett CL; Oddone E; Matchar D
    Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ethics of AIDS care.
    Harvey JC
    J Int Assoc Physicians AIDS Care; 1997 Nov; 3(11):14-24. PubMed ID: 11364809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
    Lidgren M; Hollander A; Weiland O; Jönsson B
    Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.